medigraphic.com
ISSN 1025-0255 (Electronic)

2020, Number 5

<< Back Next >>

AMC 2020; 24 (5)

Malignant neurological syndrome: about a case

Cepero-Rodríguez I, Toca-Smith LA, Frenes-Mederos B Pérez-de la Cruz V

Language: Spanish
References: 17
Page: 730-737
PDF size: 399.45 Kb.


ABSTRACT

Background: neuroleptics with an antipsychotic effect are effective in controlling the symptoms of schizophrenia, delusions and hallucinations. Neuroleptic malignant syndrome is the most serious adverse effect caused by antipsychotics.
Objective: to present an unusual case of a patient with a diagnosis of psychotic symptoms who presented a neuroleptic malignant syndrome caused by antipsychotics.
Case report: a patient who listens to voices inside his head is admitted and the doctor notes that he was hyperconcentrated and performed stereotyped movements with difficulties in wandering. At the 7th day of hospitalization he begins with generalized rigidity, tremor, language disorders and dysphagia that is interpreted as an extrapyramidal syndrome of drug cause, with increased creatinine phosphokinase (CK) levels. Bromocriptine 2.5 mg every 12 hours is used, in addition to vigorous hydration, prophylactic anticoagulation with low molecular weight heparin and periodic assessment of respiratory and renal function.
Conclusions: the malignant neurological syndrome corresponds to an idiosyncratic reaction, produced by any dopamine receptor blocker drug classically associated with high potency antipsychotic drugs such as haloperidol and fluphenazine, as observed in the case presented in the article, so it was necessary to identify the prodromal signs early and make the therapeutic changes in a timely manner in order to prevent the serious condition and restore the health of the patient with minimal risk.


REFERENCES

  1. Alvarez González R, Ramos Guevara K, Ortiz Sánchez Y, Martínez Suárez H. Prescripción de Neurolépticos en el Puesto de Salud Santa María. Enero-junio/ 2015. Brasil. Multimed [Internet]. 2015 [citado 15 Ene 2019];19(6):[aprox. 15 p.]. Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=62240.

  2. Colón Núñez S, López Santacruz YA, Brito Hernández A. Síndrome neuroléptico maligno. Presentación de un caso y revisión de la literatura. Rev Ciencias Salud. 2017;1:13-18..

  3. Bai YM, Li CT, Tsai SJ, Chen MH, Su YP. Metabolic syndrome and adverse clinical outcomes in patients with bipolar disorder. BMC Psychiatry. 2016;16(9):176-99..

  4. Jesus C, Jesus I, Agius M. What evidence is there to show which antipsychotics are more diabetogenic than others? Psychiatria Danubina. 2015;27(12):55-90..

  5. Franch Pato CM, Molina Rodriguez V, Franch Valverde JI. Síndrome metabólico y antipsicótico atípico. Posibilidad de predicción y control. Rev Psiquiat Salud Mental. 2016;10(21):112-15..

  6. León Caballero J, Alba Pale L, Salgado Serrano P, Pérez Solà V. Síndrome neuroléptico maligno con mínima elevación de creatina cinasa: breve revisión a propósito de un caso. Actas Esp Psiquiatr. 2015;43(4):194-96..

  7. Francisco Ramírez S, Bello Davila L, Hernández JF, Marín Muñoz J, Castillo G, Vargas JD, et al. Síndrome neuroléptico maligno con mielinolisis central pontina. Acta Neurol Colomb. 2018;34(4):245-249..

  8. Rodríguez Edinson Dante M. Síndrome neuroléptico maligno por risperidona. Rev Exp Med [Internet]. 2016 [citado 15 Ene 2019];2(2):73-5. Disponible en: http://rem.hrlamb.gob.pe/index.php/REM/article/view/45/41.

  9. Fernández M, Lago L, Alonso G, Guede A, Benavente JL, Olivares JM. Síndrome serotoninérgico frente a síndrome neuroléptico maligno: a propósito de un caso. Actas Esp Psiquiatr. 2018;46(2):68-74..

  10. García Atienza EM, Agudo Mena JL, Cuesta Vizcaíno E, Val Jiménez CL, Sáez Moreno MA. Olanzapina como causa de síndrome neuroléptico maligno, revisión bibliográfica a raíz de un caso clínico. Actas Esp Psiquiatr. 2018;46(3):112-16..

  11. Denis A, Vera R, Recalde A, Paats A, Esteche A. Síndrome neuroléptico maligno like. Rev Virtual Soc Parag Med Int. 2017;4(2):49-53..

  12. Saritas TB, Çankaya B, Yosunkaya A. Olanzapine-Induced Malignant Neuroleptic Syndrome. Turk J Anaesthesiol Reanim. 2014;42:288-91..

  13. Kumar Saha P, Chakraborty A, Kumar Layek A, Chakraborty A. Olanzapine-induced Neuroleptic Malignant Syndrome. Indian J Psychol Med. 2017;39:364-65..

  14. Estévez RV, Blanco ML, Castillo JJ, Merino MI, García JA. Síndrome neuroléptico maligno: dificultades en el diagnóstico diferencial. Psiquiatría Biológica. 2016;23(3):122-24..

  15. Komatsu T, Nomura T, Takami H, Sakamoto S, Mizuno K, Sekii H, et al. Catatonic Symptoms Appearing before Autonomic Symptoms Help Distinguish Neuroleptic Malignant Syndrome from Malignant Catatonia. Internal Medicine. 2016;55(19):2893-7..

  16. Sanjuán Domingo R, Villaverde Royo MV, Elías Villanueva MP, Castán S, Viñuales Luis E, Sánchez Lázaro C. Síndrome neuroléptico maligno. Med Gen Fam. 2018;7(1):32-34..

  17. Alonso Marín J, Castañeda Arango C, Palomino Camargo L, Pérez Agudelo JJ, Castro Álvarez JF. Síndrome neuroléptico maligno asociado a la administración del haloperidol. Caso clínico. Rev Toxicol. 2018;35:7-10.




2020     |     www.medigraphic.com